Sang Eun Yoon Woorim Kang Choi, Seung hyun Park, Yoon Mauricio Chalita Hyun Kim Je Hee Lee Dong-Wook Hyun Kyung Ju Ryu Hojun Sung Jae-Yun Lee Jin-Woo Bae Won seog Kim Seok-Jin Kim 2024-01-12T07:00:07Z 2024-01-12T07:00:07Z 2023-02-16 2023-05 0006-4971 https://pubs.kist.re.kr/handle/201004/80507 The gut microbiome influences cancer development and the efficacy and safety of chemotherapy but little is known about its effects on lymphoma. We obtained stool samples from treatment-naive, newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) (n = 189). We first performed 16S ribosomal RNA gene sequencing (n = 158) and then conducted whole-genome shotgun sequencing on additional samples (n = 106). We compared the microbiome data from these patients with data from healthy controls and assessed whether microbiome characteristics were associated with treatment outcomes. The alpha diversity was significantly lower in patients with DLBCL than in healthy controls (P < .001), and the microbial composition differed significantly between the groups (P < .001). The abundance of the Enterobacteriaceae family belonging to the Proteobacteria phylum was markedly higher in patients than in healthy controls. Functional analysis of the microbiome revealed an association with opportunistic pathogenesis through type 1 pili, biofilm formation, and antibiotics resistance. Enterobacteriaceae members were significantly enriched in patients who experienced febrile neutropenia and in those who experienced relapse or progression (P < .001). Interestingly, greater abundance of Enterobacteriaceae correlated with shorter progression-free survival (P = .007). The cytokine profiles of patients whose microbiome was enriched with Enterobacteriaceae were significantly associated with interleukin 6 (P = .035) and interferon gamma (P = .045) levels. In summary, patients with DLBCL exhibited gut microbial dysbiosis. The abundance of Enterobacteriaceae correlated with treatment outcomes and febrile neutropenia. Further study is required to elucidate the origin and role of gut dysbiosis in DLBCL. English American Society of Hematology The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma Article 10.1182/blood.2022018831 1 Blood, v.141, no.18, pp.2224 - 2238 Blood 141 18 2224 2238 N scie scopus 001004994700001 Hematology Hematology Article BACTERIA CANCER ALIGNMENT IMMUNITY HODGKIN CHOP RNA